Wenjing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenjing Li has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Renjun Pei
Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences
4 shared publications - Tian Gao
School of Nano-Tech and Nano-Bionics
3 shared publications - Jine Wang
Dezhou University
2 shared publications Shengkai Sun
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China
2 shared publications- Zheng Wang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China; CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China
2 shared publications - Airong Xu
Henan University of Science and Technology
1 shared publication
Latest Publications
- Open Access
- 23 October 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (44) , 10706-10716
A metal–organic framework complex for enhancing tumor treatments through synergistic effect of chemotherapy and photodynamic therapy
The La-TCPP@DOX@Apt composite nanomaterial not only avoid the side effects caused by high concentration chemotherapeutic drugs, but also can effectively inhibit and kill solid tumors under the synergistic attack of CD and PDT.
- 23 October 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (44) , 10706-10716
Open AccessA metal–organic framework complex for enhancing tumor treatments through synergistic effect of chemotherapy and photodynamic therapy
The La-TCPP@DOX@Apt composite nanomaterial not only avoid the side effects caused by high concentration chemotherapeutic drugs, but also can effectively inhibit and kill solid tumors under the synergistic attack of CD and PDT.
- 22 January 2023
- Published by Wiley in Reviews in Medical Virology
- Vol. 33 (2) , e2425
Dengue determinants: Necessities and challenges for universal dengue vaccine development
Dengue illness can range from mild illness to life‐threatening haemorrhage. It is an Aedes‐borne infectious disease caused by the dengue virus, which has four serotypes. Each serotype acts as an independent infectious agent. The antibodies against one serotype confer homotypic immunity but temporary protection against heterotypic infection. Dengue has become a growing health concern for up to one third of the world's population. Currently, there is no potent anti‐dengue medicine, and treatment for severe dengue relies on intravenous fluid management and pain medications. The burden of dengue dramatically increases despite advances in vector control measures. These factors underscore the need for a vaccine. Various dengue vaccine strategies have been demonstrated, that is, live attenuated vaccine, inactivated vaccine, DNA vaccine, subunit vaccine, and viral‐vector vaccines, some of which are at the stage of clinical testing. Unfortunately, the forefront candidate vaccine is less than satisfactory, and its performance depends on serostatus and age factors. The lessons from clinical studies depicted ambiguity concerning the efficacy of dengue vaccine. Our study highlighted that viral structural heterogeneity, epitope accessibility, autoimmune complications, genetic variants, genetic diversities, antigen competition, virulence variation, host‐pathogen specific interaction, antibody‐dependent enhancement, cross‐reactive immunity among Flaviviruses, and host‐susceptibility determinants not only influence infection outcomes but also hampered successful vaccine development. This review integrates dengue determinants allocated necessities and challenges, which would provide insight for universal dengue vaccine development.
- 22 January 2023
- Published by Wiley in Reviews in Medical Virology
- Vol. 33 (2) , e2425
Dengue determinants: Necessities and challenges for universal dengue vaccine development
Dengue illness can range from mild illness to life‐threatening haemorrhage. It is an Aedes‐borne infectious disease caused by the dengue virus, which has four serotypes. Each serotype acts as an independent infectious agent. The antibodies against one serotype confer homotypic immunity but temporary protection against heterotypic infection. Dengue has become a growing health concern for up to one third of the world's population. Currently, there is no potent anti‐dengue medicine, and treatment for severe dengue relies on intravenous fluid management and pain medications. The burden of dengue dramatically increases despite advances in vector control measures. These factors underscore the need for a vaccine. Various dengue vaccine strategies have been demonstrated, that is, live attenuated vaccine, inactivated vaccine, DNA vaccine, subunit vaccine, and viral‐vector vaccines, some of which are at the stage of clinical testing. Unfortunately, the forefront candidate vaccine is less than satisfactory, and its performance depends on serostatus and age factors. The lessons from clinical studies depicted ambiguity concerning the efficacy of dengue vaccine. Our study highlighted that viral structural heterogeneity, epitope accessibility, autoimmune complications, genetic variants, genetic diversities, antigen competition, virulence variation, host‐pathogen specific interaction, antibody‐dependent enhancement, cross‐reactive immunity among Flaviviruses, and host‐susceptibility determinants not only influence infection outcomes but also hampered successful vaccine development. This review integrates dengue determinants allocated necessities and challenges, which would provide insight for universal dengue vaccine development.
- Open Access
- 22 November 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (9) , 1871-1880
Cancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration
Cancer-associated fibroblasts (CAFs) produce a critical tumor-promoting effect by cellular crosstalk with cancer cells and remodel the extracellular matrix (ECM) to form a protective physical barrier. The simple elimination of CAFs is not sufficient to govern the CAF-shaped aggressive tumor microenvironment (TME) because of the complexity of tumors. Herein, a CAF-targeted poly (lactic-co-glycolic acid) (PLGA) nanoemulsion is tailored to simultaneously deliver doxorubicin (DOX) and small interfering RNA (siRNA) targeting hepatocyte growth factor (HGF) for the combination of chemotherapy and gene therapy. The nanoemulsion (apt-Si/DNPs) shows a high specificity towards CAFs due to the aptamer modification and efficiently induces the apoptosis of CAFs, thus decreasing ECM deposition in the TME. Importantly, the delivered siRNA reduces the expression of the HGF in the remaining CAFs, which overcomes chemotherapy-induced upregulation of HGF mRNA and prevents the reproduction of CAFs through the autocrine HGF closed-loop. Owing to these synergetic effects, tumor proliferation, migration and invasion are prominently inhibited and tumor permeability is improved significantly. Overall, these results emphasize the potential of CAF-targeted combination treatments to inhibit tumor progression and metastasis, as well as overcome therapeutic resistance.
- 22 November 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (9) , 1871-1880
Open AccessCancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration
Cancer-associated fibroblasts (CAFs) produce a critical tumor-promoting effect by cellular crosstalk with cancer cells and remodel the extracellular matrix (ECM) to form a protective physical barrier. The simple elimination of CAFs is not sufficient to govern the CAF-shaped aggressive tumor microenvironment (TME) because of the complexity of tumors. Herein, a CAF-targeted poly (lactic-co-glycolic acid) (PLGA) nanoemulsion is tailored to simultaneously deliver doxorubicin (DOX) and small interfering RNA (siRNA) targeting hepatocyte growth factor (HGF) for the combination of chemotherapy and gene therapy. The nanoemulsion (apt-Si/DNPs) shows a high specificity towards CAFs due to the aptamer modification and efficiently induces the apoptosis of CAFs, thus decreasing ECM deposition in the TME. Importantly, the delivered siRNA reduces the expression of the HGF in the remaining CAFs, which overcomes chemotherapy-induced upregulation of HGF mRNA and prevents the reproduction of CAFs through the autocrine HGF closed-loop. Owing to these synergetic effects, tumor proliferation, migration and invasion are prominently inhibited and tumor permeability is improved significantly. Overall, these results emphasize the potential of CAF-targeted combination treatments to inhibit tumor progression and metastasis, as well as overcome therapeutic resistance.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5441
Abstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
Targeting DNA damage response (DDR) pathways has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR pathway, and thus represents a promising anti-tumor target. We here report the discovery of a series of next generation RAD51 inhibitors that can prevent RAD51 foci formation and particularly, a pre-clinical candidate molecule SCR-6992 with potent anti-tumor efficacies and desirable pre-clinical development drug properties. SCR-6992 exhibits remarkable anti-proliferative potency in human lymphoma Daudi cells in vitro (IC50 = 12 nM) while has no inhibitory effect in normal human cells. The combination of SCR-6992 with chemotherapeutic agents or DDR-targeting drugs produces synergistical anti-cancer response in lymphoma and solid tumor cell lines. Furthermore, SCR-6992 significantly inhibits tumor growth in Daudi xenograft tumor model with the tumor regression observed when dosed orally at 80 mg/kg/day. SCR-6992 also shows acceptable translational drug properties and pharmacokinetic profiles in both rodents and dogs. SCR-6992 was well tolerated in rats and dogs in 14-day dose range finding studies without noted hematological or gastrointestinal toxicities, when dosed up to 200 mg/kg and 40 mg/kg, respectively. Taken together, SCR-6992 demonstrates as an effective RAD51 inhibitor with encouraging anti-tumor activities and favorable development drug properties. The clinical development plans of SCR-6992 have been formulated for hematologic malignancies and solid tumors. Citation Format: Peng Gu, Liting Xue, Ping Chen, Wenjing Li, Ya Geng, Feng Zhou, Guimei Yang, Xiaohong Hou, Chunyan Zhao, Wenqing Yang, Renhong Tang. Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5441.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5441
Open AccessAbstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
Targeting DNA damage response (DDR) pathways has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR pathway, and thus represents a promising anti-tumor target. We here report the discovery of a series of next generation RAD51 inhibitors that can prevent RAD51 foci formation and particularly, a pre-clinical candidate molecule SCR-6992 with potent anti-tumor efficacies and desirable pre-clinical development drug properties. SCR-6992 exhibits remarkable anti-proliferative potency in human lymphoma Daudi cells in vitro (IC50 = 12 nM) while has no inhibitory effect in normal human cells. The combination of SCR-6992 with chemotherapeutic agents or DDR-targeting drugs produces synergistical anti-cancer response in lymphoma and solid tumor cell lines. Furthermore, SCR-6992 significantly inhibits tumor growth in Daudi xenograft tumor model with the tumor regression observed when dosed orally at 80 mg/kg/day. SCR-6992 also shows acceptable translational drug properties and pharmacokinetic profiles in both rodents and dogs. SCR-6992 was well tolerated in rats and dogs in 14-day dose range finding studies without noted hematological or gastrointestinal toxicities, when dosed up to 200 mg/kg and 40 mg/kg, respectively. Taken together, SCR-6992 demonstrates as an effective RAD51 inhibitor with encouraging anti-tumor activities and favorable development drug properties. The clinical development plans of SCR-6992 have been formulated for hematologic malignancies and solid tumors. Citation Format: Peng Gu, Liting Xue, Ping Chen, Wenjing Li, Ya Geng, Feng Zhou, Guimei Yang, Xiaohong Hou, Chunyan Zhao, Wenqing Yang, Renhong Tang. Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5441.
- 24 February 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 10 (12) , 2057-2066
Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer
Tumor-targeted delivery of antitumor drugs is considered a promising strategy for improving the chemotherapeutic efficiency and reducing the incidence of side effects. The development of tumor-targeted aptamers to accommodate drugs has attracted great interest because of their convenience in biomedical applications. CD133 is a robust biomarker of colorectal cancer. In this study, Cs5, a novel specific aptamer with a dissociation constant in the nanomolar range, was developed using the cell-SELEX strategy from engineered CD133-expressing cells, and doxorubicin (Dox) was loaded into the Cs5 aptamer to form a chimera. The chimera showed an excellent targeting ability for CD133 through a selective killing effect in human colorectal cancer HCT116 cells expressing CD133. The in vitro and in vivo results demonstrated the highly efficient therapy and low toxicity of the chimera. Given the overexpression of CD133 in various tumors, our work provides a promising tool for specific cell identification and a wide range of applications in the field of targeted cancer therapy.
- 24 February 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 10 (12) , 2057-2066
Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer
Tumor-targeted delivery of antitumor drugs is considered a promising strategy for improving the chemotherapeutic efficiency and reducing the incidence of side effects. The development of tumor-targeted aptamers to accommodate drugs has attracted great interest because of their convenience in biomedical applications. CD133 is a robust biomarker of colorectal cancer. In this study, Cs5, a novel specific aptamer with a dissociation constant in the nanomolar range, was developed using the cell-SELEX strategy from engineered CD133-expressing cells, and doxorubicin (Dox) was loaded into the Cs5 aptamer to form a chimera. The chimera showed an excellent targeting ability for CD133 through a selective killing effect in human colorectal cancer HCT116 cells expressing CD133. The in vitro and in vivo results demonstrated the highly efficient therapy and low toxicity of the chimera. Given the overexpression of CD133 in various tumors, our work provides a promising tool for specific cell identification and a wide range of applications in the field of targeted cancer therapy.
- 20 January 2022
- Published by Elsevier in Chinese Chemical Letters
- Vol. 33 (8) , 4096-4100
Development and analysis of a novel AF11–2 aptamer capable of enhancing the fluorescence of aflatoxin B1
- 20 January 2022
- Published by Elsevier in Chinese Chemical Letters
- Vol. 33 (8) , 4096-4100
Development and analysis of a novel AF11–2 aptamer capable of enhancing the fluorescence of aflatoxin B1
- 1 November 2016
- Published by Morressier GmbH
Targeted Proteomics Analysis of CrbpI Reveals Diagnostic Value for Cancer
- 1 November 2016
- Published by Morressier GmbH
Targeted Proteomics Analysis of CrbpI Reveals Diagnostic Value for Cancer
- 15 January 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (10) , 8377-8379
Eco-friendly polysorbate aqueous solvents for efficient dissolution of lignin
Herein green, low energy consuming and inexpensive solvents (polysorbate/H2O (Tween-80/H2O)) were developed, which could be readily prepared, instantaneously dissolve lignin without any heating, and hardly disrupt the structure of lignin.
- 15 January 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (10) , 8377-8379
Eco-friendly polysorbate aqueous solvents for efficient dissolution of lignin
Herein green, low energy consuming and inexpensive solvents (polysorbate/H2O (Tween-80/H2O)) were developed, which could be readily prepared, instantaneously dissolve lignin without any heating, and hardly disrupt the structure of lignin.